Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Psychiatry Cardiology Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Anesthesiology & Pain Medicine Pulmonology & Critical Care Physical Medicine & Rehab Nephrology Emergency Medicine Urology Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

C3 glomerulopathy

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for C3 glomerulopathy

4 trials tracked for C3 glomerulopathy: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 43 citations.

4Trials tracked

1Phase 3 & 4

0Recruiting

1With published results

Phase distribution

Phase 3 1 Phase 2 3

Phase 3 Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis Completed · 43 cited
Phase 2 A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G) Completed
Phase 2 A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN Completed
Phase 2 Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.